Itero Biopharmaceuticals Appoints Debanjan Ray to Vice President, Business Development

Itero Expanding Pipeline of Differentiated Protein Therapeutics

SAN MATEO, Calif.--(BUSINESS WIRE)-- Itero Biopharmaceuticals, Inc. announced today that Debanjan Ray has been promoted to Vice President, Business Development and an Itero corporate officer. His role will be to lead business development efforts aimed at expanding the company’s pipeline of differentiated protein therapeutics.

“Debanjan was instrumental in closing the recently announced global licensing deal with Watson Pharmaceuticals for our first program,” said R. Jerald Beers, Senior Vice President and Chief Commercial Officer of Itero. “He is currently spearheading our business development efforts to expand Itero’s pipeline via in-licensing, collaborations, or the acquisition of protein drug candidates to which we can apply our extensive biologics development and commercialization knowledge and experience.” In his new role, Debanjan will continue to report directly to Mr. Beers.

“With our recent licensing transaction, Itero now has greater financial resources to invest in our pipeline. Our ability to invest, along with our experienced team and capital efficient approach, make us an ideal partner for companies with protein therapeutic candidates looking to collaborate. I think Itero can uniquely add significant value to a program,” added V. Bryan Lawlis, Ph.D., Itero President and Chief Executive Officer.

Mr. Ray joined Itero Biopharmaceuticals in 2008 as Director, Commercial Development. Before joining the company, he was Associate Director, Business Development at Portola Pharmaceuticals. Mr. Ray holds an MBA from The Wharton School, University of Pennsylvania and received his B.S. from the Massachusetts Institute of Technology.

About Itero Biopharmaceuticals, Inc.

Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over currently marketed alternatives. Itero is led by an executive team with 100+ collective years of successful experience in the development, manufacturing and commercialization of more than a dozen marketed biopharmaceuticals manufactured by recombinant DNA technology, including monoclonal antibodies. Through in-licensing, acquisition, and strategic collaboration, Itero adds substantial value to protein therapeutics by executing capital efficient process development, manufacturing, and global clinical development, and paving the way for successful regulatory review and commercialization. For additional information on Itero Biopharmaceuticals, please visit the company’s Web site at


Itero Biopharmaceuticals, Inc.
Debanjan Ray, 650-581-7906
V.P., Business Development
Kureczka Martin Associates
Joan Kureczka, 415-821-2413
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science



Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.